RJA
ARKG icon

Raymond James & Associates’s ARK Genomic Revolution ETF ARKG Stock Holding History

Raymond James & Associates’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.55M Sell
60,535
-21,876
-27% -$557K ﹤0.01% 2398
2024
Q2 		$1.93M Sell
82,411
-32,104
-28% -$810K ﹤0.01% 2190
2024
Q1 		$3.29M Sell
114,515
-4,666
-4% -$140K ﹤0.01% 1856
2023
Q4 		$3.91M Sell
119,181
-12,172
-9% -$331K ﹤0.01% 1693
2023
Q3 		$3.66M Sell
131,353
-6,054
-4% -$198K ﹤0.01% 1654
2023
Q2 		$4.68M Buy
137,407
+2,948
+2% +$92.7K ﹤0.01% 1523
2023
Q1 		$4.04M Sell
134,459
-13,222
-9% -$410K ﹤0.01% 1610
2022
Q4 		$4.17M Sell
147,681
-57,686
-28% -$1.83M ﹤0.01% 1524
2022
Q3 		$6.75M Buy
205,367
+33,730
+20% +$1.24M 0.01% 1174
2022
Q2 		$5.41M Sell
171,637
-2,887
-2% -$101K 0.01% 1350
2022
Q1 		$8.02M Sell
174,524
-46,671
-21% -$2.23M 0.01% 1199
2021
Q4 		$13.5M Sell
221,195
-42,799
-16% -$2.96M 0.01% 941
2021
Q3 		$19.7M Sell
263,994
-32,120
-11% -$2.69M 0.02% 715
2021
Q2 		$27.4M Buy
296,114
+22,443
+8% +$1.91M 0.02% 557
2021
Q1 		$24.3M Sell
273,671
-38,540
-12% -$3.82M 0.02% 576
2020
Q4 		$29.1M Buy
312,211
+4,895
+2% +$390K 0.03% 461
2020
Q3 		$19.6M Buy
307,316
+98,749
+47% +$5.79M 0.02% 547
2020
Q2 		$10.9M Buy
208,567
+109,082
+110% +$4.68M 0.01% 783
2020
Q1 		$3.11M Sell
99,485
-4,683
-4% -$156K ﹤0.01% 1316
2019
Q4 		$3.49M Sell
104,168
-108,143
-51% -$3.44M ﹤0.01% 1492
2019
Q3 		$6.27M Buy
212,311
+124,696
+142% +$4.05M 0.01% 1104
2019
Q2 		$3.02M Buy
87,615
+21,514
+33% +$690K ﹤0.01% 1537
2019
Q1 		$2.17M Buy
66,101
+25,628
+63% +$757K ﹤0.01% 1710
2018
Q4 		$971K Sell
40,473
-5,962
-13% -$168K ﹤0.01% 2110
2018
Q3 		$1.55M Buy
46,435
+25,193
+119% +$797K ﹤0.01% 1960
2018
Q2 		$617K Buy
21,242
+5,312
+33% +$148K ﹤0.01% 2537
2018
Q1 		$410K Buy
+15,930
New +$431K ﹤0.01% 2691

Other funds holding ARKG

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
MMEA
Main Management ETF Advisors San Francisco, California $3.3B AUM 33.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Raymond James & Associates's ARKG Position: Q3 2024 in Review

Raymond James & Associates reduced its ARK Genomic Revolution ETF (ARKG) stake by 27% in Q3 2024, selling an estimated $557K and leaving 60,535 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2398.

Raymond James & Associates first reported a position in ARKG in Q1 2018 and has held it in 27 quarters since. The position peaked at $29.1M in Q4 2020. 240 funds tracked by Wall St. Rank hold ARKG as of Q3 2024.

  • Raymond James & Associates held 60,535 shares of ARK Genomic Revolution ETF worth $1.55M as of Q3 2024.
  • Raymond James & Associates sold 21,876 ARK Genomic Revolution ETF shares in Q3 2024, an estimated $557K.
  • ARK Genomic Revolution ETF made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2398 holding.
  • Raymond James & Associates first reported a position in ARK Genomic Revolution ETF in Q1 2018 and has held it in 27 quarters since.
  • Raymond James & Associates's ARK Genomic Revolution ETF position peaked at $29.1M in Q4 2020.
  • 240 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.